Harbour BioMed Receives FDA IND Clearance for HBM7004 Solid Tumor Trial
CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, May 8, 2026 Harbour BioMed announced that the U.S. Food and Drug...
Cancer Immunotherapy
Advertisement
Zelluna ASA Activates First Clinical Site for ZIMA-101 Phase 1 Solid Cancer Trial
OSLO, Norway, May 6, 2026 Zelluna ASA announced the activation of the first clinical site for its ZIMA-101 Phase...
BriaCell Gains FDA Clearance for Breast Cancer Trial
PHILADELPHIA and VANCOUVER, British Columbia, May 6, 2026 BriaCell Therapeutics Corp. has received FDA clearance for its Investigational New...
Diakonos Gains FDA Fast Track for DOC1021 Melanoma
HOUSTON, May 6, 2026 Diakonos Oncology Corp., a clinical-stage biotechnology company focused on next-generation cancer immunotherapies, has announced that...
OS Therapies Secures EMA Review for OST-HER2 Drug
NEW YORK, New York, April 30, 2026 OS Therapies announced that the European Medicines Agency (EMA) has initiated a...
Advertisements
EnGeneIC Doses First Patient in GBM EDV Therapy Trial
SYDNEY, AUSTRALIA, May 01, 2026 EnGeneIC has announced a critical clinical milestone with the first patient dosed in its...
Scancell Advances Cancer Immunotherapy Pipeline Momentum
OXFORD, UK, April 28, 2026 Scancell Holdings plc, a clinical-stage biopharmaceutical company specializing in cancer immunotherapies, has reported significant...
Citius Oncology Drives LYMPHIR Adoption in Cancer Care
CRANFORD, N.J., March 31, 2026 Citius Oncology, Inc. has reported strong early momentum following the U.S. launch of its...
OS Therapies Advances OST-HER2 Toward FDA Approval
NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...
CStone CS2009 Shows Strong Phase I/II Cancer Data
Suzhou, China – March 26, 2026 CStone Pharmaceuticals announced significant clinical progress for its trispecific antibody CS2009, highlighting strong...
Advertisement
